FURO FABUNMI: Open Payments
NPI 1730719014 · RICHMOND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$358 in 14 payments from 4 companies in 2025. Trend: 2023 $326 · 2024 $164 · 2025 $358
Food & beverage: $358
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $137 |
| Otsuka America Pharmaceutical, Inc. | 3 | $112 |
| ACADIA Pharmaceuticals Inc | 3 | $68 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
Products named: INGREZZA, REXULTI, NUPLAZID, AUSTEDO XR, UZEDY.
Industry payments across TX — which companies pay providers there.
